136 related articles for article (PubMed ID: 9219551)
1. Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA.
Olivero OA; Chang PK; Lopez-Larraza DM; Semino-Mora MC; Poirier MC
Mutat Res; 1997 Jun; 391(1-2):79-86. PubMed ID: 9219551
[TBL] [Abstract][Full Text] [Related]
2. Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells.
Olivero OA; Semino C; Kassim A; Lopez-Larraza DM; Poirier MC
Mutat Res; 1995 Apr; 346(4):221-30. PubMed ID: 7753115
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin- and carboplatin-DNA adducts: is PT-AG the cytotoxic lesion?
Fichtinger-Schepman AM; van Dijk-Knijnenburg HC; van der Velde-Visser SD; Berends F; Baan RA
Carcinogenesis; 1995 Oct; 16(10):2447-53. PubMed ID: 7586150
[TBL] [Abstract][Full Text] [Related]
4. Elevated mitochondrial cisplatin-DNA adduct levels in rat tissues after transplacental cisplatin exposure.
Giurgiovich AJ; Diwan BA; Olivero OA; Anderson LM; Rice JM; Poirier MC
Carcinogenesis; 1997 Jan; 18(1):93-6. PubMed ID: 9054594
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis.
Yang Z; Schumaker LM; Egorin MJ; Zuhowski EG; Guo Z; Cullen KJ
Clin Cancer Res; 2006 Oct; 12(19):5817-25. PubMed ID: 17020989
[TBL] [Abstract][Full Text] [Related]
6. Enhanced excision repair of DNA damage due to cis-diamminedichloroplatinum(II) in resistant cervix carcinoma HeLa cells.
Chao CC
Eur J Pharmacol; 1994 Aug; 268(3):347-55. PubMed ID: 7805758
[TBL] [Abstract][Full Text] [Related]
7. Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary cells.
LeDoux SP; Wilson GL; Beecham EJ; Stevnsner T; Wassermann K; Bohr VA
Carcinogenesis; 1992 Nov; 13(11):1967-73. PubMed ID: 1423864
[TBL] [Abstract][Full Text] [Related]
8. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-DNA adduct formation in maternal and fetal rat tissues after transplacental cisplatin exposure.
Giurgiovich AJ; Diwan BA; Lee KB; Anderson LM; Rice JM; Poirier MC
Carcinogenesis; 1996 Aug; 17(8):1665-9. PubMed ID: 8761423
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
[TBL] [Abstract][Full Text] [Related]
11. Differences in the rate of DNA adduct removal and the efficiency of mutagenesis for two benzo[a]pyrene diol epoxides in CHO cells.
MacLeod MC; Daylong A; Adair G; Humphrey RM
Mutat Res; 1991 Dec; 261(4):267-79. PubMed ID: 1722282
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-DNA damage in p21WAF1/Cip1 deficient mouse keratinocytes exposed to cisplatin.
van Gijssel HE; Leil TA; Weinberg WC; Divi RL; Olivero OA; Poirier MC
Mutagenesis; 2007 Jan; 22(1):49-54. PubMed ID: 17158520
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen-DNA adduct formation in rat liver determined by immunoassay and 32P-postlabeling.
Divi RL; Osborne MR; Hewer A; Phillips DH; Poirier MC
Cancer Res; 1999 Oct; 59(19):4829-33. PubMed ID: 10519392
[TBL] [Abstract][Full Text] [Related]
14. Highly sensitive chemiluminescence immunoassay for benzo[a]pyrene-DNA adducts: validation by comparison with other methods, and use in human biomonitoring.
Divi RL; Beland FA; Fu PP; Von Tungeln LS; Schoket B; Camara JE; Ghei M; Rothman N; Sinha R; Poirier MC
Carcinogenesis; 2002 Dec; 23(12):2043-9. PubMed ID: 12507927
[TBL] [Abstract][Full Text] [Related]
15. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells.
Blommaert FA; van Dijk-Knijnenburg HC; Dijt FJ; den Engelse L; Baan RA; Berends F; Fichtinger-Schepman AM
Biochemistry; 1995 Jul; 34(26):8474-80. PubMed ID: 7599137
[TBL] [Abstract][Full Text] [Related]
16. Response of sensitive and resistant IgM immunocytomas to cis-diamminedichloroplatinum (II) does not correlate with the platination level or with the formation or removal of DNA adducts.
Vendrik CP; Fichtinger-Schepman AM; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; de Groot G; Berends GF; Steerenberg PA
Cancer Chemother Pharmacol; 1997; 39(6):479-85. PubMed ID: 9118458
[TBL] [Abstract][Full Text] [Related]
17. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
18. Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts.
Roberts JJ; Friedlos F
Cancer Res; 1987 Jan; 47(1):31-6. PubMed ID: 3791217
[TBL] [Abstract][Full Text] [Related]
19. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC
Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504
[TBL] [Abstract][Full Text] [Related]
20. Gene- and strand-specific damage and repair in Chinese hamster ovary cells treated with 4-nitroquinoline 1-oxide.
Snyderwine EG; Bohr VA
Cancer Res; 1992 Aug; 52(15):4183-9. PubMed ID: 1638532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
